Women’s Health Still Key to Bayer Despite Early Research Shift
Exit Rumors Inaccurate
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
You may also be interested in...
Astellas’ Veozah Is First-In-Class Treatment For Vasomotor Symptoms
Veozah received approval from the US FDA for a common symptom of menopause, a therapeutic area that has lacked pharmaceutical advancements.
Bayer May Not Launch In Innovation-Unfriendly European Markets
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.
Five Challenges Bill Anderson Faces At Bayer
Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.